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Imatinib  mesylate,  a  selective  tyrosine  kinase  inhibitor,  is  the  ﬁrst  line  treatment  against
chronic  myelogenous  leukemia  and  gastrointestinal  stromal  tumors.  The  aim of  the present
study is to investigate  the effects  of imatinib  mesylate  on  the  pregnant  rats  and their
fetuses.  Pregnant  rats  were divided  into  three  groups;  the  ﬁrst  group  served  as  a control
group.  The  second  and  third  groups  were  orally  administered  imatinib  at doses  of 36 mg/kg
body  weight  or  54  mg/kg  b.wt.  on gestation  days  (SDs)  6 through  13  or SDs  13 through
19,  respectively.  All  animals  were  sacriﬁced  on  the  20th  day  of gestation.  Treatment  with
imatinib  caused  a reduction  of maternal  body  weight  gain,  uterine  and  placental  weights,
increased  rate of  abortion  and fetal  resorptions.  High  dose  of  imatinib  caused  fetal  con-
genital  deformities  represented  in  harelip,  contraction  of the  fore  limbs,  and  paralysis  of
the hind  limbs,  exencephaly,  encephalocoele  and  distended  abdominal  wall,  besides  occur-
rence of  wavy  ribs and  absence  of  other  ribs  in  addition  to skeletal  growth  retardation  and
lack  of ossiﬁcation  of  the  most  skeletal  elements.  The  present  work  concluded  that  ima-
tinib is  teratogenic  when  given  orally  to  pregnant  rats  at 54  mg/kg  b.wt.  and  causes  direct
maternal  or developmental  toxicity.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pregnancy and cancer are complex situations. The treat-
ment of cancer during pregnancy is a difﬁcult problem
because of the potential effects of the therapy on the
mother and fetus [1]. Cancer, known medically as a malig-
nant neoplasm, is a broad group of various diseases, all
involving unregulated cell growth. In cancer, cells divide
and grow uncontrollably, forming malignant tumors, and
invade nearby parts of the body. Cancer may  also spread to
more distant parts of the body through the lymphatic sys-
tem or bloodstream. Not all tumors are cancerous. Benign
∗ Corresponding author at: Flat 16, 12 Asmaa Fahmey St., Heliopolis,
Cairo, Egypt. Tel.: +20 0224147745.
E-mail address: monaamhelal@yahoo.com (M.A. Helal).
http://dx.doi.org/10.1016/j.toxrep.2015.05.001
2214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/4.0/).tumors do not grow uncontrollably, nor invade neighbor-
ing tissues, and do not spread throughout the body [2].
There are over 200 different known cancers that afﬂict
humans, 90–95% of cases attributed to environmental fac-
tors and 5–10% are due to genetics [3]. Researchers have
long searched for a more selective method of targeting
cancer cells exclusively. The ideal drug would “zero in” on
cancer cells and leave other body cells unharmed. Recently,
the drug imatinib, which is referred to as a “guided mis-
sile” against cancer has captured the interest of oncologists
[4]. It is the ﬁrst anticancer drug to speciﬁcally inhibit a
molecular abnormality unique to human cancer cells. Ima-
tinib selectively inhibits BCR-ABL gene which has been
identiﬁed being the cause of chronic myeloid leukemia
and was approved by the United States of America FDA
as a ﬁrst line treatment for chronic myeloid leukemia
[5].
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Imatinib is rapidly absorbed when given by mouth, and
s highly bioavailable: 98% of an oral dose reaches the
loodstream. Metabolism of imatinib occurs in the liver
nd is mediated by several isozymes of the cytochrome
450 system, including CYP3A4 and, to a lesser extent,
YP1A2, CYP2D6, CYP2C9, and CYP2C19. The main metabo-
ite, N-demethylatedpiperazine derivative, is also active.
he major route of elimination is in the bile and feces; only
 small portion of the drug is excreted in the urine. Most
f imatinib is eliminated as metabolites; only 25% is elim-
nated unchanged. The half-lives of imatinib and its main
etabolite are 18 and 40 h, respectively. It blocks the activ-
ty of Abelson cytoplasmic tyrosine kinase (ABL), c-Kit and
he platelet-derived growth factor receptor (PDGFR). As an
nhibitor of PDGFR, imatinib mesylate appears to have util-
ty in the treatment of a variety of dermatological diseases.
matinib has been reported to be an effective treatment for
IP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic
yndrome, and dermatoﬁbrosarcoma protuberans [6].
Although imatinib is an effective therapy for newly
iagnosed CP-CML patients, 40–45% of patients discon-
inue treatment due to adverse events (20–25%) or imatinib
esistance (20%) [7]. Importantly, 7–8% of patients trans-
orm to accelerated phase (AP) or blast crisis (BC), with
ost transformations occurring within the ﬁrst 3 years of
matinib therapy [7,8]. Treatment with imatinib is gener-
lly well tolerated, and the risk for severe adverse effects
s low. Adverse effects most commonly include mild-to-
oderate edema, nausea and vomiting, diarrhea, muscle
ramps, and cutaneous reactions. Hepatic transaminase
evel elevations and myelosuppression occur less fre-
uently and resolve with interruption of imatinib therapy
9].
The beneﬁcial effects of treatment with imatinib in
regnant patients with chronic myelogenous leukemia
hould be balanced with the risk of teratogenicity and con-
enital abnormality in fetus. The risk of teratogenicity has
een variable and in most cases it is low and is not well
stablished. A more extensive surveillance is needed for
etter decision making in treating pregnant women with
hronic myelogenous leukemia [10]. So, the aim of the
resent study is to investigate the possible side effects from
he use of imatinib on the pregnant rats and their fetuses.
. Material and methods
.1. Animals
Total number of 40 adult female Sprague Dawley rats
eighing 150–170 g and 20 male rats weighing 150 g of
he same strain were obtained from the Farm of National
rganization for Drug Control and Research. Animals had
ree access to tap water and to standard food diet ad
ibitum. All rats were allowed to adapt to the laboratory
nvironment for 1 week before being used. The experi-
ental procedures complied with the guidelines of the
ommittee on Care and Use of National Organization for
rug Control and Research Center, Cairo, Egypt. Each two
dult virgin females in proestrus were caged overnight in
n animal plastic cage with normal mature male. Vagina
as examined daily for suggesting pregnancy by a vaginaleports 2 (2015) 654–663 655
smear technique according to the method of Matthews
and Kenyon [11]. Females with positive vaginal smears
were considered pregnant at zero day of gestation.
2.2. Chemical used
Imatinib mesylate ﬁlm-coated tablets containing
imatinib mesylate equivalent to 100 mg  of imatinib free
base was used (Novartis.Com, Switzerland). Imatinib
mesylate is designated chemically as 4-[(4-Methyl-1-
piperazinyl) methyl]-N-[4-methyl-3-[[4-(3-yridinyl)-2-
pyrimidinyl]amino]-phenyl] benzamidemethanesulfonate
and its structural chemical formula is
Imatinib mesylate is a white to yellowish tinged
crystalline powder. Its molecular formula is C29H31N7O·
CH4SO3 and it has low molecular weight which is
493.603 g/mol. Imatinib mesylate is freely soluble in water
and aqueous buffers ≤pH 5.5.
2.3. Experimental design and procedures
All pregnant rats were divided into three main groups.
The ﬁrst main group (about 8 animals) served as control.
The second main group was  divided into two  subgroups (8
rats each) and was orally administered low dose of ima-
tinib mesylate free base pure active compound (36 mg/kg
body weight dissolved in 1 ml distilled water) on gesta-
tion days (SDs) 6 through 13 and on SDs 13 through 19.
The third main group of pregnant rats was  divided into
two subgroups (8 rats/each) and was  orally administered
high dose of imatinib (54 mg/kg b.wt.) dissolved in 1 ml
distilled water from 6th day to 13th day of gestation and
from 13th day to 19th day of gestation, respectively. The
drug doses (36 mg/kg and 54 mg/kg) are related to the low
and high human therapeutic doses [12–15]. The drug doses
(36 mg/kg and 54 mg/kg) were chosen in the present work
as the dose 36 mg/kg body weight is considered the lowest-
observed-adverse-effect level (LOAEL) of imatinib that can
cause the least developmental toxic effects and mortal-
ity rate to the pregnant rats and their fetuses. Lower than
36 mg/kg showed no observed adverse effect level (NOAEL)
of imatinib. The dose equal to 54 mg/kg b.wt. was consid-
ered as the maximum dose that can cause direct maternal
and developmental toxicity. Higher than 54 mg/kg b.wt.
showed complete mischarge and increased percentage of
dams mortality rates. At the 20th day of gestation – one day
before the date of expected delivery, because mothers usu-
ally cannibalize malformed or incompletely vital neonates
[16] – pregnant females are sacriﬁced. The ovaries and
uteri from each female were removed and examined for
the number of corpora lutea, status of all the implantation
sites (i.e., live and dead fetuses, early and late resorptions
cology R656 M.M. El Gendy et al. / Toxi
and total implantations sites). A resorption site was deﬁned
as an implantation site resembling a brown to greenish
blood clot, with just placental tissue [early resorption] or
with placental and embryonic tissue [late resorption] [17].
A non-viable fetus – still birth – which was described as
a fetus that does not react to stimuli, has a pale color,
stemming from a lack of blood ﬂow, and is smaller in size
compared to the viable fetuses. The number of alive and
dead fetuses was recorded. Each live fetus was dried on a
bloating paper, weighed and subsequently, the fetal weight
and crown rump length were measured. Each fetus was
examined carefully for any congenital anomalies. Fetuses
were ﬁxed in 96% ethanol solution for skeletal anomalies.
Alterations were classiﬁed as malformations (rare struc-
tural changes) or anomalies (minor structural differences
from normal detected relatively frequently). The percent-
age of pre-implantation loss and post-implantation loss
was calculated according to the following equations:
Pre-implantation loss = (number of corpora
lutea) − (number of implantation sites)/number of corpora
lutea × 100.
Post-implantation loss = (number of implantation
sites) − (number of viable fetuses)/number of implantation
sites × 100.
2.4. Skeletal preparations of fetuses
For the skeletal studies, fetuses of rats were skinned
and ﬁxed in 96% ethanol for 5 days for dehydration. Stain-
ing was performed with alcian blue–alizarin red solution
according to the method described by Taylor [18], which is
prepared by dissolving (15 mg  alcian blue stain in 80 ml
96% ethanol + 20 ml  of glacial acetic acid). Then fetuses
were immersed in a solution containing 0.01 g alizarin red
stain dissolved in 100 ml  of 1% aqueous KOH. Clearing pro-
cess was done by placing the fetuses in 2% aqueous KOH
solution for 7 days, until skeletons were clearly visible
through the surrounding tissue. After staining, the speci-
mens were transferred to ascending series of glycerol in 1%
aqueous potassium hydroxide solution, after which, they
were preserved in 100% glycerin. The stained preparations
were carefully examined under the dissecting binocular
microscope to study the various parts of the axial and
appendicular skeleton for any abnormalities.
2.5. Statistical analysis
Statistical signiﬁcance was evaluated by one-way
ANOVA using SPSS Version 19 and the individual compari-
son was obtained by LSD method. Values were considered
statistically signiﬁcant when p < 0.05.
3. Results
3.1. Effect of imatinib on the pregnant ratsMaternal food and water consumption were slightly
decreased (non-signiﬁcantly) as compared to the control
group and no obvious clinical observations were noticed in
the treated groups.eports 2 (2015) 654–663
3.1.1. Body weight
In the present study, the average maternal body weights
for the control and experimental subgroups recorded on
the 1st, 6th, 13th and 19th days of gestation were rep-
resented in Fig. 1. The data indicated that the pregnant
females of both the control and all experimental groups
showed a steady increase in the body weight (weight gain)
during the ﬁrst week of gestation before administration of
imatinib. On the 13th day of gestation, the body weight
of rats of the control group continued to increase approx-
imately at the same rate, while those of the experimental
subgroups showed a less rate of increase in the body weight
gain. On the 19th day, pregnant females of the control group
exhibited high percentage of body weight gain (31.79%).
The rate of increase in weight of the treated subgroups
decreased than the control one being 26.51% and 27% for
animals that were treated with the low dose of imatinib
from the 6th day to the 13th day and from the 13th day to
the 19th day of pregnancy, respectively, while those which
were treated with high dose of imatinib from the 6th day
to the 13th day recorded (23.01%) and from the 13th day
to the 19th day recorded (22.62%) from control group.
3.1.2. Percentage of abortion
No abortions were recorded among mothers of control
group. On the other hand, two  cases of complete abortions
were recorded in subgroup (25%) which were treated with
the low dose of imatinib (36 mg/kg b.wt.) from the 6th to
the 13th day of gestation, while no abortions were recorded
in the subgroup treated with imatinib at the same dose
from the 13th to the 19th day of gestation compared to the
normal control group. Treatment with high dose (54 mg/kg
body weight) of imatinib from the 6th to the 13th day
of gestation recorded three cases of complete abortions
(37.5%) and two cases (25%) of abortions were recorded
in the subgroup treated with imatinib from the 13th to
the 19th day of gestation as compared to control group.
Abortions among rats of both treated groups occurred on
the 13th or the 19th day of gestation. A sudden drop in
maternal body weight and presence of drops of blood were
considered as signs of abortion.
3.1.3. Percentage of resorption
Uteri with partial and complete resorption sites were
calculated and recorded in Table 1. There was  no resorp-
tion among the control group (Fig. 2) or in the subgroup
treated with imatinib at 36 mg/kg body weight from the 6th
to the 13th day of gestation. On contrary, the percentage of
uteri with partial resorption in rats administered the same
dose of imatinib from the 13th to the 19th day of gestation
recorded 62.5% compared to the normal values. Pregnant
rats treated with imatinib (54 mg/kg b.wt.) exhibited about
62.5% of uteri with partial resorption (Fig. 2b and c), while
the percentage of uteri with complete resorption recorded
about 12.5% as shown in Fig. 2.3.1.4. Average weight of uteri and placenta
The effect of imatinib on the weight of uteri and placenta
of pregnant rats for control and all treated groups were
recorded in Table 1.
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n. G4 = Subgroup treated with high dose of imatinib (54 mg/kg) from
(16.06 ± 4.36) and (15.28 ± 5.69) respectively, exhibited a
highly signiﬁcant (p < 0.01, p < 0.001) reduction than those
of the control group (35.52 ± 0.70).
3.1.4.2. Average weight of placenta. The average weight
of placenta exhibited a signiﬁcant decrease (p < 0.05) at
36 mg/kg imatinib from the 6th to the 13th recorded
(1.0 ± 0.15) and from the 13th to the 19th day of ges-
tation recorded (0.87 ± 0.17) compared to the control
group (1.53 ± 0.08). While the average weight of placenta
revealed a very highly signiﬁcant decrease (p < 0.001) at
54 mg/kg imatinib from the 6th to the 13th day of gesta-
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 54 mg/kg b.wt. of imatinib on the 20th day of gestation showing partial
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day of gestation recorded (0.53 ± 0.18) as compared to the
control group. The data were given in Table 1.
3.2. Effect of imatinib on the fetuses
3.2.1. External morphological studies
The mean number of fetal body weight and length were
recorded in (Table 2). Growth retardation was  indicated by
the reduction of both fetal body weight and body length.
The average fetal body weight and length in the two exper-
imental subgroups, treated with imatinib at both doses,
were less than that of the control group.Morphological
examination of fetuses maternally treated with high dose
of imatinib exhibited several abnormal external features
as internal hemorrhage, congestion and growth retarda-
tion. Also, hematoma (subcutaneous hemorrhage or dark
red patches under the skin) was found mainly in the head,
in the back between shoulders and between fore and hind
limbs. Harelip appeared as congenital cleft in the midline
of the upper lip (Fig. 3b). Encephalocoele and protrusion of
the brain tissue through a congenital ﬁssure in the skull,
abdominal distention and internal hemorrhage were also
noticed (Fig. 3c and d), besides anomalies of limbs that
were indicated by contraction of the fore limb and paral-
ysis of the hind limb (Fig. 3d). In the fetuses maternally
treated with the high dose of gleevec from the 13th to the
19th day of gestation, anomalies were also veriﬁed partic-
ularly in the fore and hind limbs that were rotated inward.
In addition to, some fetuses exhibited edema and internal
hemorrhage (Fig. 3b and c). No obvious abnormal changes
in the fetuses internal organs were noticed in the treated
groups. Table 4 illustrated the total number of fetuses with
external anomalies.
3.2.2. Mortality rate
The total prenatal mortality rate was  represented by
fetal resorptions and stillbirths (dead fetuses). On the 20th
day of gestation all dead and alive fetuses were calculated
and recorded in Table 3. There were no mortality rates
among the control and experimental subgroup maternally
treated with low dose (36 mg/kg b.wt.) of imatinib from
the 6th to the13th day of gestation, while mortality rate
of fetuses maternally treated with the same dose from
the 13th to the 19th of gestation was  found to be 36.76%
from the control group. The rate of dead fetuses mater-
nally treated with high dose of imatinib (54 mg/kg b.wt.)
from the 6th to the 13th and from the 13th to the 19th
was  18.18% and 64.28% respectively as compared to the
control group. Administration of imatinib at low dose from
the 13th to the 19th of gestation increased the percentage
of pre-implantation loss to 11.69% and post-implantation
loss to 36.76% as compared with control group. Even more,
high dose of imatinib elevated the percentage of pre-
implantation loss and post-implantation loss to 29.09% and
30.77% respectively, in the group of rats given imatinib
from the 6th to the 13th day of gestation and also in the
group of rats given imatinib from the 13th to the 19th day
of gestation to reach 17.65% and 64.29% respectively from
normal control group (Table 3).
M.M. El Gendy et al. / Toxicology Reports 2 (2015) 654–663 659
Table  2
Effect of imatinib on fetuses body weight and length.
Parameters Control Imatinib low dose
(6th–13th)
Imatinib low dose
(13th–19th)
Imatinib high dose
(6th–13th)
Imatinib high dose
(13th–19th)
Mean body weight (g) (±SE) 4.55 ± 0.09 3.47 ± 0.13 3.09 ± 0.12 2.56 ± 0.11 2.11 ± 0.16
C%  of change – −23.74 −32.09 −43.74 −53.63
p  Value – a***c*d***e*** a***b*d**e*** a***b***c** a***b***c***
Mean body length (cm) (±SE) 5.24 ± 0.06 4.56 ± 0.08 4.12 ± 0.10 3.81 ± 0.11 3.16 ± 0.15
C%  of change – −12.97 −21.37 −27.29 −33.69
p  Value – a***c***d***e*** a***b***d*e*** a***b***c*e*** a***b***c***d***
a = compared to the normal control.
b  = compared to the low dose of imatinib (36 mg/kg) from 6th to 13th day of gestation.
c  = compared to the low dose of imatinib (36 mg/kg) from 13th to 19th day of gestation.
d  = compared to the high dose of imatinib (54 mg/kg) from 6th to 13th day of gestation.
e  = compared to the high dose of imatinib (54 mg/kg) from 13th to 19th day of gestation.
C% = percentage of change from normal control.
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(* Signiﬁcant (p < 0.05).
** Highly signiﬁcant (p < 0.01).
*** Very highly signiﬁcant (p < 0.001).
.2.3. Skeletal studies
.2.3.1. Control cases. At the 20th day of gestation, the
leared cartilage and bone preparations of control rat
etuses have designated that the skeletal system shows
umerous bony elements stained with alizarin and few
artilages stained with alcian blue. These cases, well illus-
rated in (Fig. 4a), were displaying the developed cartilage
nd bone in the different parts of skeleton of these control
etuses.
.2.3.2. Fetuses maternally treated mothers. Fetuses of
others treated with imatinib during gestation have
xhibited several skeletal alterations as compared with
ontrol ones. Bones of the skull of 20 days old fetuses mater-
ally treated with low dose of imatinib (36 mg/kg b.wt.)
rom the 6th to the13th day of gestation, showed mild
egree of lack of ossiﬁcation of frontal, parietal, interpar-
tal, squamosal and occipital bones of the skull (Fig. 4b).
ess ossiﬁcation of the cervical, thoracic, lumber, sacral and
audal vertebrae of the vertebral column was also noticed.
wenty days old fetuses maternally treated with imatinib
ig. 3. Photograph of control fetus (a). (b–d) Fetuses on the 20th day of gestation m
arelip with congenital cleft in the midline of the upper lip (b). Encephalocoele w
bdominal distention and internal hemorrhage (c). Exencephaly (Ex) and the brain
cr)  of the fore limb and paralysis (pl) of the hind limb (d).(36 mg/kg b.wt.) from the 13th to the19th day of gesta-
tion revealed, retardation of ossiﬁcation of scapulae and
clavicles of the pectoral girdle and also the bones of the
fore limbs (humerus, radius, ulna, carpals, metacarpals and
phalanges). Moreover, less ossiﬁcation of the bones of the
pelvic girdle (ilium, ischium and pubis) and the bones of
the hind limbs (femur, tibia, ﬁbula, tarsals, metatarsals and
phalanges) were also seen. The fore and hind limbs not only
showed lower degree of ossiﬁcation but also became more
shorter and thinner as compared with the corresponding
bones of the control fetuses (Fig. 4a). In addition, some
fetuses had wavy ribs; numbers 7, 8, and 9 and the last
rib (number 13) were lost (Fig. 4c).
Fetuses of dams treated with (54 mg/kg b.wt.) imatinib
from the 6th to the13th day and the 13th to the19th
day of gestation showed severe lack of ossiﬁcation of the
dermal bones of the skull and bones of the upper and
lower jaws. Also, the effect of imatinib on the pectoral
and pelvic girdles of the fetuses maternally treated with
high dose of imatinib was manifested by severe shortness
and lack of ossiﬁcation of all their bones and reduction
aternally treated with the high dose of gleevec (54 mg/kg b.wt.) showing:
ith protrusion of the brain tissue through a congenital ﬁssure in the skull,
 are completely exposed through a defect in the cranial vault, contraction
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of the ossiﬁcation parts of both scapulae and clavicles as
compared with those of the control. The long bones of
the fore and hind limbs of these fetuses whose mothers
were treated with high dose of imatinib were considerably
shorter, thinner and less ossiﬁed, compared with those of
the control but the phalangeal formula was  still the same
as that of the control 2:3:3:3:3 (Fig. 4d). In addition to the
above mentioned lesions, some fetuses had wavy ribs in
number; 7, 8, and 9 as shown in Fig. 4e in addition to severe
lack of ossiﬁcation and shortness of the vertebral column
(cervical, thoracic, lumbar and sacral vertebrae). However,
vertebral column showed non-ossiﬁcation of their central
and neural arches. Moreover, the caudal vertebrae were
absolutely non-ossiﬁed in all treated groups.
4. Discussion
Although the chemotherapy drug imatinib mesylate is
used to treat certain types of cancer (e.g., chronic myeloid
leukemia, gastrointestinal stromal tumors, and myelodys-
plastic/myeloproliferative diseases) by stopping or slowing
the growth of cancer cells (tumors) and causing cancer cells
to die. This medication can increase the risk of fetal malfor-
mation when administered to the pregnant rats. Imatinib
mesylate was  found to be teratogenic in rats when admin-
istered during organogenesis period at dose 54 mg/kg b.wt.
It caused reduction of maternal body weight, uterine and
placental weights. It increased the percentages of pre- and
post-implantation loss, percentage of abortion, resorptions
and caused fetal growth retardation with respect to normal
control group. Fetuses maternally treated with the ima-
tinib mesylate suffered from subcutaneous hemorrhage,
hematoma, contraction in the fore limbs and paralysis
in the hind limbs, in addition to the presence of hare-
lip, exencephaly, encephalocoele and distended abdominal
wall. Moreover, Skeletal examination of 20-day old fetuses
showed wavy ribs (numbers 7, 8, and 9), absence of rib
number 13 and incomplete ossiﬁcation of some skeletal
elements such as skull bones, vertebral column, sternum,
ribs, vertebrae, pectoral girdle, fore limb bones, pelvic gir-
dle and hind limb bones.
From the results of the present work, it was found that
the ﬁrst noticed effect of imatinib on the pregnant rats
was  the reduction of body weight gain in the experimen-
tal groups than in the control group. The rate of reduction
in body weight increased as the dose of imatinib was
increased being 26.51% and 27% for animals that were
treated with the low dose of imatinib from the 6th day
to the 13th day and from the 13th day to the 19th day of
pregnancy, respectively. While, those which were treated
with high dose of imatinib from the 6th day to the 13th
day recorded (23.01%) and from the 13th day to the 19th
day recorded (22.62%) from control group. Similar results
were recorded by Chabner et al. [19] and Togo et al. [20],
as they stated that many anticancer drugs damage the
epithelial cells of the digestive tract, resulting anorexia,
nausea, vomiting, malabsorption and all of these effects
can cause the reduction of the body weight. In accordance
with the present results, El-Sayyad et al. [21] found a sig-
niﬁcant decrease in the body weight gain after treatment
of rats with therapeutic doses of many anticancer drugs
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Fig. 4. (a) Photograph of the skeletal system of 20 days old control fetus showing: well ossiﬁed skull (S), cervical (CRV), thoracic (THV), lumbar (LV), sacral
(SV),  caudal vertebrae (CV) and hind limbs (HL). (b) Photograph of fetus maternally treated with imatinib (36 mg/kg) from 6th to 13th day of gestation
showing: retardation of ossiﬁcation of skull (S), upper jaw (UJ), Lower jaw (LJ) and presence of wavy ribs (WR). (c) Skeleton of fetuses maternally treated
with  imatinib (36 mg/kg) from 13th to 19th of gestation showing incomplete ossiﬁcation of cervical (CRV), thoracic vertebrae (THV), metacarpals (MC),
metatarsals (MT) and phalanges (PH). Absence of the last rib (LR) (no. 13) and a fetus had wavy ribs (WR) (nos. 7, 8, and 9). (d) Skeleton of fetuses on the
20th  day of gestation maternally treated with imatinib (54 mg/kg) from 6th to 13th day of gestation showing sever lack of ossiﬁcation of scapulae (SC)
and  clavicles (Cl) bones of the pectoral girdle (PG). Lack of ossiﬁcation of pelvic girdle (PLG) and humerus (HU), radius (RA), ulna (UL), metacarpals (MC)
and  phalanges (PH) of the fore limb (FL). Femur (FE), tibia (TI), ﬁbula (FI), metatarsals (MT) and phalanges (PH) of the hind limb (HL) showed lower degree
of  ossiﬁcation, shorter and thinner as compared to the control fetus (a). (e) Severe lack of ossiﬁcation of cervical (CRV), thoracic vertebrae (THV), lumbar
vertebrae (LV) and sacral vertebrae (SV). Severe rib anomalies: wavy ribs (WR) on rib numbers 7, 8, and 9 and absence of the last rib (LR) number 13.
Table 4
Total number of fetuses with external anomalies (%).
No of fetuses with
external anomalies (%)
Control Imatinib low
dose
(6th–13th)
Imatinib low
dose
(13th–19th)
Imatinib high
dose
(6th–13th)
Imatinib high
dose
(13th–19th)
Harelip 0 0 0 15 (38.46) 6 (14.29)
Exencephaly 0 0 0 10 (25.64) 4 (9.52)
Encephalocoele 0 0 0 4 (10.26) 3 (7.14)
Paralysis of the hind limb 0 2 (4.88) 3 (4.41) 2 (5.13) 1 (2.38)
Contraction of the fore limb 0 3 (7.32) 3 (4.41) 3 (7.69) 1(2.38)
Congestion 0 2 (4.88) 4 (5.88) 3 (7.69) 2 (4.76)
Subcutaneous hemorrhage 0 0 1(1.47) 7 (17.95) 5 (11.90)
Hematoma 0 0 0 3 (7.69) 0
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as cisplatin, doxorubicin (1 mg/kg) and 5-FU (20 mg/kg)
for 20 days as compared to control group and the authors
attributed that to hepatotoxicity which might have con-
tributed to this loss as previously reported by King and
Perry [22]. The second harmful action on mothers was  rep-
resented by high percentage of abortions (37.5%) which
was noticed in the treated group injected with the high
dose of imatinib (54 mg/kg b.wt.) from the 6th to the 13th
as compared with the other treated groups and (25%) were
recorded in the subgroup treated with imatinib from 13th
to 19th day of gestation as compared to control group. Our
results are in agreement with many authors [23,24] who
found the same results in animal studies and in patients
treated with different chemotherapy agents. The authors
added that, increased risk of abortion, birth defects, genetic
or neoplastic disease in the offspring of cancer survivors
may  be caused from germ cells injury as well as induction
of transmissible genetic damage.
Placental transfer of imatinib to fetuses during preg-
nancy may  be one of the reasons which led to the increased
numbers of resorption and abortion in the treated groups.
In conﬁrmation with the present suggestion, many reports
established the penetration of anticancer drugs through the
placental barrier. Busulfan crosses the placenta and causes
incidence of abortion in rhesus monkeys [25] and severe
stunting of growth, fetal malformations and gonadal apla-
sia in the offspring of rats [26]. Inhibition of DNA synthesis
has the potential to cause abortion, intrauterine growth
retardation and congenital malformations after treatment
with both hydroxyurea and busulfan [27].
In the present work, administration of imatinib to
pregnant rats caused high percentage of fetal mortal-
ity including resorptions and stillbirths, thus leading to
a decrease in maternal uterine weights in both treated
groups compared with the control group. Comparing
between the two treated groups (36 and 54 mg/kg b.wt.
imatinib) it was  clear that the decrease in the average uter-
ine weight was proportional to the dose of imatinib. Similar
results were recorded by Chung et al. [28] and Yeh et al. [29]
in pregnant rats treated with different doses of anticancer
drugs. Slott and Hales [30] and Higdon et al. [31] stated that,
cisplatin and carboplatin are reported to be distributed in
the uterine tissues in human, rats, and rabbits. Further-
more, there are persistent DNA adducts in the uterine tissue
of rats [32]. Anticancer drug has also been shown to cause
apoptosis in primary endometrial cell cultures [33]. It is
possible that the administration of cisplatin causes uterine
damage, and that damage to the uterus will either prevent
implantation, leading to the increased pre-implantation
loss, or will lead to damage that prevents the implanted
fetuses from developing, leading to the increased post-
implantation loss, or a combination of both. In accordance
with the present results, Chung et al. [34] found an increase
in the resorption rate in pregnant rats which were admin-
istered platinum compound and DA-125 from the 6th to
the16th day of gestation. The authors suggested that the
resorption may  be as a result of insufﬁcient hormone con-
centration, deﬁcient placenta function or may  be due to the
direct effect of heptaplatin on the embryos.
In the present study, treatment with imatinib caused
fetal growth retardation indicated by reduction of botheports 2 (2015) 654–663
body weight and length of the fetuses. Our results are in
agreement with Bajt and Aggarwal [35], as they elucidated
that, reduction in the number of fetuses and their body
weights during organogenesis were linked to its efﬁcacy in
reducing the levels of pituitary hormones. Hormones, such
as progesterone, prolactin and LH, are necessary for normal
embryonic and fetal development. Their imbalance, due to
the exposure of dams to chemotherapy, might result in a
delay of embryonic and fetal development. The intrauter-
ine development in mammals is a period of active cell
proliferation, migration and differentiation and it is highly
sensitive to chemical injuries. A number of effects, ranging
from pre- and postnatal mortality and stunting of growth to
severe organ malformation, and functional anomalies have
been reported to result from chemical exposure to embryos
[36]. Vandyke et al. [37] reported that the rapid accelera-
tion of growth plate closure resulting from the inhibition
of PDGF- receptor signaling by imatinib placental hypop-
erfusion and consequently fetal hypoperfusion.
Imatinib induced various teratogenic pictures in fetuses
maternally treated with imatinib (36 and 54 mg/kg b.wt.)
from the 6th day to the 13th day and from the 13th
day to the 19th day of pregnancy. These pictures were
manifested by hemorrhage, hematoma, contraction of the
fore limbs, paralysis in hind limbs, lack of ossiﬁcation of
the skeleton and reduced birth weight and length. Also,
encephalocoele, exencephaly, distended abdominal wall
with internal hemorrhage and harelip were noticed only in
the fetuses maternally treated with the high dose of ima-
tinib. Similar observations were recorded by Howle and
Gale [38] as they found that, cis-platinum complexes have
been reported to induce a severe and prolonged inhibition
of DNA synthesis with minimal effects on RNA and pro-
tein synthesis. The complexes appear to produce a partial
denaturation of DNA and an almost complete destruction of
protein secondary structure [39]. Many chemotherapeutic
agents are teratogenic, and they also inhibit DNA synthesis.
The relationship between the inhibition of DNA synthesis
and the production of malformations is not clear [40]. It
may  be interference with cell proliferation and induction
of cell death that often follows inhibition of DNA synthe-
sis that is responsible for the production of malformations.
Ault et al. [41] and Pye et al. [42] found that pregnant
women  treated for chronic myeloid leukemia and exposed
to imatinib by trimester were known to have resulted
infants with abnormalities. Ognio et al. [43] found that the
formation of reactive free radicals seems to be an important
part of the embryonic cytotoxicity. The reductions in uter-
ine blood ﬂow may  be associated with the embryo toxicity
[44]. Nystrom et al. [45] claimed that, in rats, imatinib has
been shown to be teratogenic. The theoretical mechanisms
responsible for the teratogenicity of the drug include inhi-
bition of platelet-derived growth factor beta (PDGFR-beta)
that is important for the development of the microvascu-
lar system and for myelination of the peripheral nervous
system.5. Conclusions
Exposure to imatinib during pregnancy has adverse
effects on pregnant rats and their fetuses. Imatinib
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